Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primovax – Phase III GV1001 plus gemcitabine vs gemcitabine in unresectable pancreatic cancer
2005-005014-21Phase 3Terminated
- Sponsor
- Pharmexa
- Start
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of tertomotide in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Pharmexa. Primary endpoint: Overall survival. Started Feb 2006; status: terminated.
02
Drugs
tertomotide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2005-005014-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005014-21.